The FDA on May 10, 2017 granted accelerated approval to KEYTRUDA® in combination with ALIMTA® (Pemetrexed) and Carboplatin for the treatment of patients with previously untreated metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC). KEYTRUDA® is a product of Merck and Co., Inc.
Bottom Ad
Advertisement
Subscribe
